Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Medication for atrial fibrillation (AF) with antiarrhythmic drugs (AAD) has been in use for almost 100 years and today remains an essential part of the treatment in patients with this condition. The goals of drug treatment include reducing the number, duration and symptoms of atrial fibrillation episodes, reducing mortality and hospitalizations as well as improving the patients’ quality of life. AAD use is limited by adverse effects which include proarrhythmia, negative inotropic and non-cardiovascular toxicity. Despite these limitations, AAD medication is, universally, the method most widely used to treat and prevent atrial fibrillation (AF) and research is ongoing to develop new attractive molecules in this pathology. The clinical use of AAD must be guided, primarily by the risk of toxicity, and then by their effectiveness.
Source: Preventing Recurrences: Classic and Modern Antiarrhythmic Drugs in Atrial Fibrillation
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi